| 0 (0%) | 01-14 09:37 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1006.27 | 1-year : | 1071.88 |
| Resists | First : | 861.54 | Second : | 917.71 |
| Pivot price | 824.48  |
|||
| Supports | First : | 770.66 | Second : | 641.19 |
| MAs | MA(5) : | 802.7 |
MA(20) : | 831.68 |
| MA(100) : | 815.98 |
MA(250) : | 688.44 |
|
| MACD | MACD : | -19.8 |
Signal : | -16.5 |
| %K %D | K(14,3) : | 24.5 |
D(3) : | 18 |
| RSI | RSI(14): 40 |
|||
| 52-week | High : | 934.61 | Low : | 510.05 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ARGX ] has closed above bottom band by 34.1%. Bollinger Bands are 0% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 816.83 - 819.97 | 819.97 - 823.58 |
| Low: | 792.95 - 796.34 | 796.34 - 800.24 |
| Close: | 804.19 - 809.64 | 809.64 - 815.92 |
Wed, 14 Jan 2026
New Analyst Forecast: $ARGX Given $1000 Price Target - Quiver Quantitative
Wed, 14 Jan 2026
Wedbush Reiterates Outperform Rating for ARGX with $1000 PT | AR - GuruFocus
Tue, 13 Jan 2026
Argenx (ARGX) Gains FDA Priority Review for Expanded Vyvgart Use - GuruFocus
Tue, 13 Jan 2026
A Quick Look at Today's Ratings for Argenx SE(ARGX.US), With a Forecast Between $900 to $1,006 - 富途牛牛
Tue, 13 Jan 2026
Argenx Vyvgart label expansion gets FDA priority review (ARGX) - Seeking Alpha
Mon, 12 Jan 2026
How Investors Are Reacting To argenx (ENXTBR:ARGX) Leadership Shift And Expanding Immunology Pipeline - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 62 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 51 (%) |
| Shares Short | 1,880 (K) |
| Shares Short P.Month | 1,840 (K) |
| EPS | 23.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 99.66 |
| Profit Margin | 41.6 % |
| Operating Margin | 30.3 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 95.5 % |
| Gross Profit (p.s.) | 32.8 |
| Sales Per Share | 59.76 |
| EBITDA (p.s.) | 11.71 |
| Qtrly Earnings Growth | 272.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 34.71 |
| PEG Ratio | 0 |
| Price to Book value | 8.13 |
| Price to Sales | 13.56 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|